Where can I buy sparsentan/sparsentan through regular channels?

Sparsentan is mainly used to treat primary immunoglobulin A nephropathy (IgAN). It has not been officially launched in mainland China, has not been included in the drug catalog approved by the State Food and Drug Administration, and has not been included in the medical insurance system. Therefore, if patients need to use this drug, they must obtain it through formal overseas channels. The original drug of sparsentan was developed by the American company Travere Therapeutics. The trade name is Filspari. The main specifications are 200mg×30 tablets and 400mg×30 tablets, which are suitable for daily oral treatment. The drug will be approved for marketing in the United States in 2023. Because of its unique target, the patent is still under protection, and the price is relatively high. The current monthly treatment cost in the United States and European markets ranges from approximately US$3,000 to US$4,000, excluding shipping and service fees.

In this context, some patients turn to overseas generic drugs. Currently, the more common generic version is 400 mg × 30 tablets produced by LUXUS Pharmaceuticals in Laos. Its main ingredients are the same as the original version, but the price is only about a quarter of the original version, making it more economical and practical. Patients should focus on the source and quality of drugs when purchasing. It is recommended to place orders through legally qualified third-party pharmaceutical service agencies, cross-border medical platforms or overseas channels to avoid purchasing counterfeit drugs or storing expired drugs due to unknown channels. It is necessary to ensure that the drugs are accompanied by English instructions, original manufacturer logos and valid batch numbers.

Since Sparsentan is a prescription drug, you still need to upload an English prescription issued by a doctor when purchasing drugs on some international e-commerce platforms. It is recommended that patients consult a doctor to formulate a medication plan before purchasing, and conduct regular monitoring of liver and kidney function during medication. In the future, the drug is expected to start local clinical research and registration processes in China. Once the approval is completed, it may be included in the medical insurance negotiation catalog. By then, domestic patients will be able to obtain this breakthrough treatment more economically and safely.

Reference materials:https://www.sparsentan.com/